Our data suggest that HSP90β promotes the growth and sorafenib resistance of HCC cells by suppressing STUB1‐induced YTHDF2 ubiquitination and degradation, which could inaugurate a novel intervention strategy for the clinical treatment of HCC. The gene discussed is HSP90AB1; the disease is hepatocellular carcinoma.